Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00371189 · ClinicalTrials.gov registry record · Phase 1
Adenovirus Vaccine for Malaria
A Phase 1 study of Plasmodium Falciparum Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 2
- Study locations
NCT00371189: Completed Phase 1 study of Plasmodium Falciparum Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00371189 is a Phase 1 study of Plasmodium Falciparum Infection that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 75 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00371189, a Phase 1 study of Plasmodium Falciparum Infection, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
Malaria is caused by a parasite carried by a mosquito. Currently, there is no vaccine licensed to prevent malaria. The purpose of this study is to find the most effective and safest dose of an experimental vaccine for the treatment of malaria. Participants will include 72 healthy adults, ages18 to 45, enrolled at Vanderbilt University Medical Center and Stanford University. Volunteers will receive 3 doses of either the malaria vaccine or placebo (contains no vaccine) by injection into a muscle at 0, 1 and 6 months. Investigators will evaluate how the body responds to increasing dosage strengths of the vaccine. Study procedures include physical exam, multiple blood draws, and completion of a memory aid (diary). Each participant will be actively involved in the study for about 12 months. Then, an annual phone call will be made to check for any serious illness events for a period of 5 years.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Ad35.CS.01 Circumsporozoite Malaria Vaccine
Study Locations (2)
California
- Stanford University School of Medicine - Stanford
Tennessee
- Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2007-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
What the finished NCT00371189 record still lists
NCT00371189 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Plasmodium Falciparum Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00371189 reports a single indexed study location in California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00371189 about?
NCT00371189 is a clinical study titled "Adenovirus Vaccine for Malaria". Malaria is caused by a parasite carried by a mosquito. Currently, there is no vaccine licensed to prevent malaria. The purpose of this study is to find the most effective and safest dose of an experimental vaccine for the treatment of malaria. Participants will include 72 healthy adults, ages18 to 4...
What is the current status of trial NCT00371189?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2007-01. Estimated completion is 2014-06.
What conditions does trial NCT00371189 study?
This clinical trial studies the following conditions: Plasmodium Falciparum Infection.
What interventions are being tested in trial NCT00371189?
The interventions under investigation include: Placebo (DRUG), Ad35.CS.01 Circumsporozoite Malaria Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00371189?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00371189 being conducted?
This trial has 2 study locations across California, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00371189's enrollment target sits among peer trials
75 711th of 2000 higher than 1,276 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia